SiteBridge Research Announces Bridging the Gap for Clinical Trials Art Contest
Using the potential of art to stimulate important conversations, the Bridging the Gap for Clinical Trials Art Contest will bind multiple levels of influence—individual, social/cultural, organizational, community, and public policy to advance diversity in clinical trials.
Clinical trial professionals can get involved through the following options:
- Becoming a sponsor or collaborator—community engagement (which is different from patient recruitment, patient engagement, and patient communities) is a relatively new concept in the clinical trial space. This contest offers the opportunity to collaborate with/sponsor an event designed to promote diversity in clinical trials and create awareness and understanding about clinical trial participation. Clinical trial participants are at the center of the industry. Without the participants, there would be no clinical trials, and therefore, no trialist profession.
- Spreading the news on social media.
- Participating—clinical trial professionals who also have an artistic side are welcome to enter any of the three categories, as long as they have no conflict of interest as outlined in the contest rules.
For more information on entry, sponsorship opportunities, categories, and rules, visit the contest's homepage here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
